Search
Advertisement
neetu chandra sharma
Neetu Chandra Sharma

Neetu Chandra Sharma

tvtn

neetu.chandra@aajtak.com

Neetu Chandra Sharma is a Senior Editor at Business Today, where she leads the magazine’s coverage of healthcare and pharmaceuticals. With o...

SHOW MORE...

Follow Neetu Chandra Sharma on:

The WHO estimates that more than 57 million people worldwide are living with dementia, and nearly 10 million new cases are diagnosed every year (AI generated)

Here's what WHO's recommendations on air pollution, obesity risks mean for India

by Neetu Chandra Sharma |Jul 16, 2026

New global guidance also recommends tackling obesity, diabetes, and hearing loss; AIIMS and NIMHANS experts contributed to the report

IHH is listed in Malaysia and Singapore

IHH is scaling India investments. Here’s what it means

by Neetu Chandra Sharma |Jul 13, 2026

The healthcare major says India will anchor global support operations as it expands hospitals, diagnostics, and health-tech investments

PB Fintech said technology-enabled care coordination will form the backbone of the model.

Policybazaar’s hospital entry: Can PB Health connect care, cover and tech?

by Neetu Chandra Sharma |Jul 13, 2026

PB Fintech has opened its first hospital in Gurugram as it seeks to bring medical care, insurance and technology together under the PB Health brand.

Dr Reddy's Flags Semaglutide Supply Delay After API Issue; Stock Falls Nearly 6%

Dr Reddy's Flags Semaglutide Supply Delay After API Issue; Stock Falls Nearly 6%

by Sakshi Batra |Jul 9, 2026

Dr. Reddy's Laboratories has announced a delay in the commercial supply of its semaglutide drug after identifying an issue with the active pharmaceutical ingredient (API) in certain batches. In this v...

The launch comes as India, home to more than 101 million people with diabetes, continues to grapple with one of the world's largest diabetes burdens.

Diabetes care gets easier: Novo Nordisk launches once-weekly insulin at ₹261 a week

by Neetu Chandra Sharma |Jul 9, 2026

India becomes seventh market for Awiqli as drugmaker targets delays in insulin initiation among people with diabetes.

Far beyond mortality, the report said cancer remains one of the biggest causes of financial hardship for households.

Cancer is leaving more children without mothers; India among six hardest-hit countries, says WHO

by Neetu Chandra Sharma |Jul 9, 2026

WHO warns global cancer cases to hit 35 million by 2050. Nearly 40% of cancers are preventable, but rising obesity, physical inactivity and unequal access to care threaten progress.

How Zaynich will drive Wockhardt’s next phase of growth

How Zaynich will drive Wockhardt’s next phase of growth

by Neetu Chandra Sharma |Jul 7, 2026

After spending nearly Rs 6,800 crore and more than two decades, Wockhardt has achieved what no Indian pharmaceutical company has before: US FDA approval for a novel drug discovered and developed in-ho...

Novo Nordisk Launches Awiqli, World’s First Weekly Basal Insulin In India

Novo Nordisk Launches Awiqli, World’s First Weekly Basal Insulin In India

by Neetu Chandra Sharma |Jul 9, 2026

Novo Nordisk has launched Awiqli (insulin icodec), the world’s first once-weekly basal insulin, in India. The company says the therapy could reduce the injection burden from 365 to 52 annually and hel...

Semaglutide Market Enters New Phase; Generics Dominate, Innovators Hold Ground

Semaglutide Market Enters New Phase; Generics Dominate, Innovators Hold Ground

by Sakshi Batra |Jul 8, 2026

India's weight-loss drug market is entering a new phase. According to Pharmatrac's June Indian Pharmaceutical Market data, the rapid expansion of the injectable semaglutide market has started to slow ...

Fortis Healthcare currently operates 36 healthcare facilities, including joint ventures and O&M hospitals, across 12 states and Union Territories

Fortis enters Odisha with 300-bed hospital through asset-light partnership

by Neetu Chandra Sharma |Jul 3, 2026

Hospital chain signs O&M agreement with Dion Group for greenfield multi-speciality facility in Cuttack as it expands beyond its existing markets.